Markt oder Branche auswählen:
| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | ||
|---|---|---|---|---|---|
| ALNYLAM PHARMACEUTICALS | 11 | 9 | -0,31 % | ||
| BRIDGEBIO PHARMA | 11 | - | +0,37 % | ||
| AGIOS | 10 | 8 | 0,00 % | ||
| BIONTECH | 7 | 13 | -0,11 % | ||
| ULTRAGENYX | 6 | - | +0,50 % | ||
| MODERNA | 5 | 16 | -0,74 % | ||
 | NOVOCURE | 5 | 11 | -2,74 % | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 5 | 3 | -1,15 % | ||
| NEUROCRINE BIOSCIENCES | 4 | 17 | -0,34 % | ||
| CRISPR THERAPEUTICS | 4 | 1 | 0,00 % |
- 24 h
- 7 Tage
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 03:24 | Coherus Oncology, Inc. Announces Pricing of Public Offering of Common Stock | 1 | GlobeNewswire (USA) | ||
| 02:31 | Why Alnylam Pharmaceuticals Stock Slipped Today | 3 | The Motley Fool | ||
| 01:06 | PacBio Q4 2025 slides: Revenue growth and margin expansion driven by human genomics | 1 | Investing.com | ||
| 00:18 | Vertex Q4 2025 slides: revenue up 9%, renal pipeline advances | 5 | Investing.com | ||
| Do | PTC Therapeutics drops as it pulls Translarna NDA resubmission | 1 | Seeking Alpha | ||
| Do | Earnings roundup: Neurocrine slumps, Alnylam battles skeptics and Ascendis eyes a competitor | 3 | BioPharma Dive | ||
| Do | PTC Therapeutics: Aktie fällt nach Rückzug des Zulassungsantrags für Translarna | 1 | Investing.com Deutsch | ||
| Do | Ultragenyx enttäuscht mit Umsatzprognose für 2026 - Aktie gibt nach | 1 | Investing.com Deutsch | ||
| Do | Agios outlines path to profitability and targets $45M-$50M in 2026 PK deficiency revenue as AQVESME U.S. launch progresses | 3 | Seeking Alpha | ||
| Do | PTC THERAPEUTICS, INC. - 8-K, Current Report | 3 | SEC Filings | ||
| Do | CRISPR Therapeutics AG - 10-K, Annual Report | - | SEC Filings | ||
| Do | Freedom Capital Markets downgrades Amgen stock rating to Hold from Buy | 4 | Investing.com | ||
| Do | CRISPR Therapeutics Earnings Report: Q4 Overview | 1 | Benzinga.com | ||
| Do | Trotz starker Zahlen: Freedom Kapitalmärkte stuft Amgen auf "Halten" herab | 2 | Investing.com Deutsch | ||
| Do | Ultragenyx: EPS verfehlt Schätzungen um 0,14 $ - Umsatz besser als erwartet | 2 | Investing.com Deutsch | ||
| Do | CRISPR Therapeutics AG: CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results | 2 | GlobeNewswire (USA) | ||
| Do | CRISPR Therapeutics AG - 8-K, Current Report | 1 | SEC Filings | ||
| Do | Vertex Pharmaceuticals Inc. Reports Rise In Q4 Bottom Line | 276 | AFX News | CAMBRIDGE (MASSACHUSETTS) (dpa-AFX) - Vertex Pharmaceuticals Inc. (VRTX) reported earnings for its fourth quarter that Increases, from last yearThe company's earnings came in at $1.191 billion... ► Artikel lesen | |
| Do | Insights into Pacific Biosciences Q4 Earnings | 7 | Benzinga.com | ||
| Do | SUPERNUS PHARMACEUTICALS, INC. - 8-K, Current Report | 4 | SEC Filings |
1 2 3 4 5 Weiter >>
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.